XML 48 R36.htm IDEA: XBRL DOCUMENT v3.25.3
Collaborative Research and Development Agreements - Narrative (Details)
 3 Months Ended 9 Months Ended
Jan. 31, 2025
USD ($)
Nov. 24, 2023
USD ($)
Oct. 23, 2020
USD ($)
Sep. 30, 2025
USD ($)
milestone
Sep. 30, 2024
USD ($)
milestone
Sep. 30, 2025
USD ($)
milestone
Sep. 30, 2024
USD ($)
milestone
Disaggregation of Revenue [Line Items]              
Collaboration revenue       $ 76,320,000 $ 30,017,000 $ 126,354,000 $ 48,167,000
Other (expense) income, net       0 (5,000) 5,433,000 (7,000)
GSK | GlaxoSmithKline Collaboration | PD-1 (Jemperli/Dostarlimab)              
Disaggregation of Revenue [Line Items]              
Agreement term following first commercial sale or expiration of the last to expire patent (in years)     12 years        
GSK | Royalties              
Disaggregation of Revenue [Line Items]              
Collaboration revenue       26,300,000 15,000,000 66,600,000 33,200,000
GSK | Royalty Agreement, Up To $1.0 billion | PD-1 (Jemperli/Dostarlimab)              
Disaggregation of Revenue [Line Items]              
Royalty percent on net sales (as a percent)     8.00%        
Net sales royalty     $ 1,000,000,000        
GSK | Royalty Agreement, Above $1. 0 billion Below $1.5 Billion | PD-1 (Jemperli/Dostarlimab)              
Disaggregation of Revenue [Line Items]              
Royalty percent on net sales (as a percent)     12.00%        
GSK | Royalty Agreement, Above $1. 0 billion Below $1.5 Billion | Minimum | PD-1 (Jemperli/Dostarlimab)              
Disaggregation of Revenue [Line Items]              
Net sales royalty     $ 1,000,000,000        
GSK | Royalty Agreement, Above $1. 0 billion Below $1.5 Billion | Maximum | PD-1 (Jemperli/Dostarlimab)              
Disaggregation of Revenue [Line Items]              
Net sales royalty     $ 1,500,000,000        
GSK | Royalty Agreement, Above $1. 5 billion Below $2.5 Billion | PD-1 (Jemperli/Dostarlimab)              
Disaggregation of Revenue [Line Items]              
Royalty percent on net sales (as a percent)     20.00%        
GSK | Royalty Agreement, Above $1. 5 billion Below $2.5 Billion | Minimum | PD-1 (Jemperli/Dostarlimab)              
Disaggregation of Revenue [Line Items]              
Net sales royalty     $ 1,500,000,000        
GSK | Royalty Agreement, Above $1. 5 billion Below $2.5 Billion | Maximum | PD-1 (Jemperli/Dostarlimab)              
Disaggregation of Revenue [Line Items]              
Net sales royalty     $ 2,500,000,000        
GSK | Royalty Agreement, Above $2.5 billion | PD-1 (Jemperli/Dostarlimab)              
Disaggregation of Revenue [Line Items]              
Royalty percent on net sales (as a percent)     25.00%        
Net sales royalty     $ 2,500,000,000        
GSK | Jemperli Royalty Monetization Agreement              
Disaggregation of Revenue [Line Items]              
Collaboration revenue       24,900,000 13,800,000 63,200,000 30,100,000
GSK | Zejula Royalty Monetization Agreement              
Disaggregation of Revenue [Line Items]              
Collaboration revenue       1,400,000 1,200,000 3,400,000 3,100,000
GSK | Zejula revenue prior to the Zejula Royalty Monetization Agreement              
Disaggregation of Revenue [Line Items]              
Collaboration revenue         1,200,000   3,100,000
GSK | First commercial sales milestone | PD-1 (Jemperli/Dostarlimab)              
Disaggregation of Revenue [Line Items]              
Collaboration revenue         $ 15,000,000   $ 15,000,000
Number of milestone | milestone         1   1
Revenue recognition milestone annual sales threshold         $ 250,000,000   $ 250,000,000
GSK | Third commercial sales milestone | PD-1 (Jemperli/Dostarlimab)              
Disaggregation of Revenue [Line Items]              
Collaboration revenue       $ 50,000,000.0   $ 50,000,000  
Number of milestone | milestone       1   1  
Revenue recognition milestone annual sales threshold       $ 750,000,000   $ 750,000,000  
Vanda | Exclusive License Agreement              
Disaggregation of Revenue [Line Items]              
Royalty percent on net sales (as a percent) 10.00%            
Upfront payment $ 15,000,000            
Other (expense) income, net       0   5,400,000  
Transaction costs expensed       2,500,000   2,500,000  
Vanda | Exclusive License Agreement | License              
Disaggregation of Revenue [Line Items]              
Collaboration revenue       0   9,600,000  
Upfront payment 10,000,000            
Vanda | Exclusive License Agreement | Transition services revenue              
Disaggregation of Revenue [Line Items]              
Collaboration revenue       100,000   200,000  
Vanda | Exclusive License Agreement | Existing drug supply              
Disaggregation of Revenue [Line Items]              
Upfront payment $ 5,000,000            
Centessa Pharmaceuticals (UK) Limited (Centessa) | GlaxoSmithKline Collaboration              
Disaggregation of Revenue [Line Items]              
Potential future payments   $ 10,000,000   $ 10,000,000   $ 10,000,000  
Centessa Pharmaceuticals (UK) Limited (Centessa) | GlaxoSmithKline Collaboration | License Agreement, Centessa Pharmaceuticals (UK) Limited              
Disaggregation of Revenue [Line Items]              
Cash payment   4,000,000          
Transaction costs incurred   300,000          
Reimbursement   3,000,000          
Total transferred   $ 7,300,000